Researchers reported Nov. 19 at the American Heart Association scientific session in Dallas that at three months 85 percent of patients with nonvalvular atrial fibrillation treated with rivaroxaban had continued to take the anticoagulant compared with 76 percent of patients on warfarin.
The real-world study was designed to compare the effectiveness, safety and persistence in use of rivaroxaban (Xarelto, Janssen Pharmaceuticals/Bayer HealthCare) and warfarin in patients with atrial fibrillation who are at risk of stroke and systemic embolism. The study found no significant difference in effectiveness and safety and showed the risk of treatment discontinuation was lower for rivaroxaban.
Winnie W. Nelson of Janssen presented the findings. Janssen funded the study.